PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.71%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-1.40%
Negative yoy D&A while RVPH is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-49.10%
Both cut yoy SBC, with RVPH at -56.99%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
5.95%
Less working capital growth vs. RVPH's 125.07%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.80%
Negative yoy AP while RVPH is 101.70%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
823.30%
Growth well above RVPH's 159.63%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
59.87%
Well above RVPH's 81.82%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-19.06%
Negative yoy CFO while RVPH is 38.83%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
96.37%
CapEx growth of 96.37% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.44%
We reduce yoy invests while RVPH stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
92.69%
Debt repayment above 1.5x RVPH's 52.51%, indicating stronger deleveraging. David Dodd would verify if expansions are not neglected.
-1494.87%
Negative yoy issuance while RVPH is 4129.39%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.